The stock of Ventyx Biosciences Inc (VTYX) has gone down by -16.42% for the week, with a 58.21% rise in the past month and a 61.68% rise in the past quarter. The volatility ratio for the week is 5.04%, and the volatility levels for the past 30 days are 7.36% for VTYX. The simple moving average for the past 20 days is 5.84% for VTYX’s stock, with a 16.82% simple moving average for the past 200 days.
Is It Worth Investing in Ventyx Biosciences Inc (NASDAQ: VTYX) Right Now?
Additionally, the 36-month beta value for VTYX is 0.91. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for VTYX is 63.06M and currently, short sellers hold a 10.68% ratio of that float. The average trading volume of VTYX on June 17, 2025 was 1.42M shares.
VTYX) stock’s latest price update
Ventyx Biosciences Inc (NASDAQ: VTYX)’s stock price has plunge by -12.80relation to previous closing price of 2.54. Nevertheless, the company has seen a -16.42% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-17 that The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at 43.25% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.66% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Nuss John, who sale 1,887 shares at the price of $1.07 back on Apr 02 ’25. After this action, Nuss John now owns 467,226 shares of Ventyx Biosciences Inc, valued at $2,019 using the latest closing price.
Nuss John, the CHIEF SCIENTIFIC OFFICER of Ventyx Biosciences Inc, sale 21,119 shares at $2.36 during a trade that took place back on Dec 27 ’24, which means that Nuss John is holding 464,582 shares at $49,841 based on the most recent closing price.
Stock Fundamentals for VTYX
The total capital return value is set at -0.57. Equity return is now at value -46.04, with -42.35 for asset returns.
Based on Ventyx Biosciences Inc (VTYX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -10.33.
Currently, EBITDA for the company is -133.77 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.57.
Conclusion
In conclusion, Ventyx Biosciences Inc (VTYX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
